Skip to main content
Top
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

RETRACTED ARTICLE: Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2

Authors: Yang Li, Xianfeng Zhang, Dawei Chen, Chengyuan Ma

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

It has been shown that let-7a was associated with the tumorigenesis of glioma. Our study was designed to infer how let-7a targets high-mobility AT-hook 2 (HMGA2) and suppresses glioma cell proliferation, invasion, and migration. Glioma tissues from 60 glioma patients and 10 normal brain tissues were collected in this study. Real-time quantitative reverse transcription-PCR (qRT-PCR) and in situ hybridization were used to detect the expression levels of let-7a in tissues and cells. The HMGA2 and the proteins related to transforming growth factor-beta (TGF-β)/Smad3 signaling pathway were measured by immunohistochemistry and western blot. Glioma U87 cells were transfected with either let-7a mimics, HMGA2 small interfering RNA (siRNA), let-7a mimics + HMGA2, HMGA2, or scramble. A cell counting kit-8 (CCK-8) assay was used to detect and compare the difference among various transfection groups. Glioma tumor xenograft models on mice were built to evaluate the effects of let-7a and HMGA2 siRNA on glioma tumors in vivo. The expression level of let-7a significantly downregulated in glioma tissues, while the HMGA2 positive expression rate notably increased compared with those in normal brain tissues (all P < 0.05). Moreover, the expression levels of let-7a and HMGA2 were correlated with glioma grades (all P < 0.05). The proliferation of U87 cells transfected with let-7a mimics or HMGA2 siRNA was significantly inhibited in comparison to the blank control group and the apoptosis rates of U87 cells transfected with let-7a mimics or HMGA2 siRNA were significantly higher than those in the blank control group (all P < 0.05). Let-7a or HMGA2 siRNA could remarkably attenuate the invasion and migration ability of glioma cells (all P < 0.05). Apart from that, over-expressed exogenous HMGA2 could reverse the inhibition of glioma cell metastasis and proliferation induced by let-7a. As suggested by immunohistochemistry and western blot, the expression levels of TGF-β1 and p-Smad3 significantly decreased compared with the blank or scramble group (all P < 0.05). Thus, let-7a and HMGA2 siRNA could effectively suppress the growth of tumors in glioma xenograft models. Let-7a may suppress the proliferation and invasion of glioma cells through mediating TGF-β/Smad3 signaling pathway by targeting HMGA2.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res. 2015;163:1–14.PubMed Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res. 2015;163:1–14.PubMed
2.
go back to reference Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16:896–913.PubMedPubMedCentral Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16:896–913.PubMedPubMedCentral
3.
go back to reference Choudhury SR, Cui Y, Milton JR, Li J, Irudayaraj J. Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma. Clin Epigenetics. 2015;7:107.PubMedPubMedCentral Choudhury SR, Cui Y, Milton JR, Li J, Irudayaraj J. Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma. Clin Epigenetics. 2015;7:107.PubMedPubMedCentral
4.
go back to reference Monroig-Bosque Pdel C, Rivera CA, Calin GA. MicroRNAs in cancer therapeutics: “from the bench to the bedside”. Expert Opin Biol Ther. 2015;15:1381–5.PubMed Monroig-Bosque Pdel C, Rivera CA, Calin GA. MicroRNAs in cancer therapeutics: “from the bench to the bedside”. Expert Opin Biol Ther. 2015;15:1381–5.PubMed
5.
go back to reference Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113:569–73.PubMedPubMedCentral Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113:569–73.PubMedPubMedCentral
6.
go back to reference Egeland NG, Lunde S, Jonsdottir K, Lende TH, Cronin-Fenton D, Gilje B, et al. The role of MicroRNAs as predictors of response to tamoxifen treatment in breast cancer patients. Int J Mol Sci. 2015;16:24243–75.PubMedPubMedCentral Egeland NG, Lunde S, Jonsdottir K, Lende TH, Cronin-Fenton D, Gilje B, et al. The role of MicroRNAs as predictors of response to tamoxifen treatment in breast cancer patients. Int J Mol Sci. 2015;16:24243–75.PubMedPubMedCentral
7.
go back to reference Das AV, Pillai RM. Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis. Cancer Cell Int. 2015;15:92.PubMedPubMedCentral Das AV, Pillai RM. Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis. Cancer Cell Int. 2015;15:92.PubMedPubMedCentral
8.
go back to reference Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.PubMed Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.PubMed
10.
go back to reference Yang G, Zhang W, Yu C, Ren J, An Z. MicroRNA let-7: Regulation, single nucleotide polymorphism, and therapy in lung cancer. J Cancer Res Ther. 2015;11(Suppl):c1–6.PubMed Yang G, Zhang W, Yu C, Ren J, An Z. MicroRNA let-7: Regulation, single nucleotide polymorphism, and therapy in lung cancer. J Cancer Res Ther. 2015;11(Suppl):c1–6.PubMed
11.
go back to reference Wu L, Nguyen LH, Zhou K, de Soysa TY, Li L, Miller JB, et al. Precise expression levels balance organ regeneration against tumor suppression. Elife. 2015. doi:10.7554/eLife.09431. Wu L, Nguyen LH, Zhou K, de Soysa TY, Li L, Miller JB, et al. Precise expression levels balance organ regeneration against tumor suppression. Elife. 2015. doi:10.​7554/​eLife.​09431.
12.
go back to reference Chen KJ, Hou Y, Wang K, Li J, Xia Y, Yang XY, et al. Reexpression of Let-7g microRNA inhibits the proliferation and migration via K-Ras/HMGA2/snail axis in hepatocellular carcinoma. Biomed Res Int. 2014;2014:742417.PubMedPubMedCentral Chen KJ, Hou Y, Wang K, Li J, Xia Y, Yang XY, et al. Reexpression of Let-7g microRNA inhibits the proliferation and migration via K-Ras/HMGA2/snail axis in hepatocellular carcinoma. Biomed Res Int. 2014;2014:742417.PubMedPubMedCentral
13.
go back to reference Wang XR, Luo H, Li HL, Cao L, Wang XF, Yan W, et al. Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN. Neuro Oncol. 2013;15:1491–501.PubMedPubMedCentral Wang XR, Luo H, Li HL, Cao L, Wang XF, Yan W, et al. Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN. Neuro Oncol. 2013;15:1491–501.PubMedPubMedCentral
14.
go back to reference Yan S, Han X, Xue H, Zhang P, Guo X, Li T, et al. Let-7f inhibits glioma cell proliferation, migration, and invasion by targeting periostin. J Cell Biochem. 2015;116:1680–92.PubMed Yan S, Han X, Xue H, Zhang P, Guo X, Li T, et al. Let-7f inhibits glioma cell proliferation, migration, and invasion by targeting periostin. J Cell Biochem. 2015;116:1680–92.PubMed
15.
go back to reference Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014;505:212–7.PubMed Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014;505:212–7.PubMed
16.
go back to reference Xi YN, Xin XY, Ye HM. Effects of HMGA2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells. Asian Pac J Trop Med. 2014;7:289–92.PubMed Xi YN, Xin XY, Ye HM. Effects of HMGA2 on malignant degree, invasion, metastasis, proliferation and cellular morphology of ovarian cancer cells. Asian Pac J Trop Med. 2014;7:289–92.PubMed
17.
go back to reference Tan L, Wei X, Zheng L, Zeng J, Liu H, Yang S, et al. Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML. J Cancer Res Clin Oncol. 2015. doi:10.1007/s00432-015-2036-9. Tan L, Wei X, Zheng L, Zeng J, Liu H, Yang S, et al. Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML. J Cancer Res Clin Oncol. 2015. doi:10.​1007/​s00432-015-2036-9.
18.
19.
go back to reference Liu B, Pang B, Hou X, Fan H, Liang N, Zheng S, et al. Expression of high-mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas. Hum Pathol. 2014;45:1752–8.PubMed Liu B, Pang B, Hou X, Fan H, Liang N, Zheng S, et al. Expression of high-mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas. Hum Pathol. 2014;45:1752–8.PubMed
20.
go back to reference Drabsch Y, ten Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012;31:553–68.PubMed Drabsch Y, ten Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012;31:553–68.PubMed
21.
go back to reference Macias MJ, Martin-Malpartida P, Massague J. Structural determinants of Smad function in TGF-beta signaling. Trends Biochem Sci. 2015;40:296–308.PubMedPubMedCentral Macias MJ, Martin-Malpartida P, Massague J. Structural determinants of Smad function in TGF-beta signaling. Trends Biochem Sci. 2015;40:296–308.PubMedPubMedCentral
22.
go back to reference Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–84.PubMed Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–84.PubMed
23.
go back to reference Han J, Alvarez-Breckenridge CA, Wang QE, Yu J. TGF-beta signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5:945–55.PubMedPubMedCentral Han J, Alvarez-Breckenridge CA, Wang QE, Yu J. TGF-beta signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5:945–55.PubMedPubMedCentral
24.
go back to reference Jiang F, Wang X, Liu Q, Shen J, Li Z, Li Y, et al. Inhibition of TGF-beta/SMAD3/NF-kappaB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells. Toxicol Lett. 2014;231:55–61.PubMed Jiang F, Wang X, Liu Q, Shen J, Li Z, Li Y, et al. Inhibition of TGF-beta/SMAD3/NF-kappaB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells. Toxicol Lett. 2014;231:55–61.PubMed
25.
go back to reference Chen HS, Bai MH, Zhang T, Li GD, Liu M. Ellagic acid induces cell cycle arrest and apoptosis through TGF-beta/Smad3 signaling pathway in human breast cancer MCF-7 cells. Int J Oncol. 2015;46:1730–8.PubMed Chen HS, Bai MH, Zhang T, Li GD, Liu M. Ellagic acid induces cell cycle arrest and apoptosis through TGF-beta/Smad3 signaling pathway in human breast cancer MCF-7 cells. Int J Oncol. 2015;46:1730–8.PubMed
26.
go back to reference Sun J, Liu SZ, Lin Y, Cao XP, Liu JM. TGF-beta promotes glioma cell growth via activating Nodal expression through Smad and ERK1/2 pathways. Biochem Biophys Res Commun. 2014;443:1066–72.PubMed Sun J, Liu SZ, Lin Y, Cao XP, Liu JM. TGF-beta promotes glioma cell growth via activating Nodal expression through Smad and ERK1/2 pathways. Biochem Biophys Res Commun. 2014;443:1066–72.PubMed
27.
go back to reference Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, et al. HMGA2 is a driver of tumor metastasis. Cancer Res. 2013;73:4289–99.PubMedPubMedCentral Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, et al. HMGA2 is a driver of tumor metastasis. Cancer Res. 2013;73:4289–99.PubMedPubMedCentral
28.
go back to reference Brat DJ, Scheithauer BW, Fuller GN, Tihan T. Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol. 2007;17:319–24.PubMedPubMedCentral Brat DJ, Scheithauer BW, Fuller GN, Tihan T. Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol. 2007;17:319–24.PubMedPubMedCentral
29.
go back to reference Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15:429.PubMed Tutar Y. miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol. 2014;15:429.PubMed
30.
go back to reference Xia T, Li J, Cheng H, Zhang C, Zhang Y. Small-molecule regulators of MicroRNAs in biomedicine. Drug Dev Res. 2015;76:375–81.PubMed Xia T, Li J, Cheng H, Zhang C, Zhang Y. Small-molecule regulators of MicroRNAs in biomedicine. Drug Dev Res. 2015;76:375–81.PubMed
31.
go back to reference Garg M. Emerging role of microRNAs in cancer stem cells: implications in cancer therapy. World J Stem Cells. 2015;7:1078–89.PubMedPubMedCentral Garg M. Emerging role of microRNAs in cancer stem cells: implications in cancer therapy. World J Stem Cells. 2015;7:1078–89.PubMedPubMedCentral
32.
go back to reference Liu K, Zhang C, Li T, Ding Y, Tu T, Zhou F, et al. Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1. Int J Oncol. 2015;46:2526–34.PubMed Liu K, Zhang C, Li T, Ding Y, Tu T, Zhou F, et al. Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1. Int J Oncol. 2015;46:2526–34.PubMed
33.
go back to reference Wang YY, Ren T, Cai YY, He XY. MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression. Cancer Biother Radiopharm. 2013;28:131–7.PubMed Wang YY, Ren T, Cai YY, He XY. MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression. Cancer Biother Radiopharm. 2013;28:131–7.PubMed
34.
go back to reference Cai K, Wan Y, Sun G, Shi L, Bao X, Wang Z. Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells. Oncol Rep. 2012;28:2101–6.PubMed Cai K, Wan Y, Sun G, Shi L, Bao X, Wang Z. Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells. Oncol Rep. 2012;28:2101–6.PubMed
35.
go back to reference Ma J, Fang B, Ma C, Pang H, Zeng F, Xia J. Proanthocyanidins inhibit pancreatic cancer AsPC-1 cell growth and migration through up-regulation of let-7a. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35:1110–5.PubMed Ma J, Fang B, Ma C, Pang H, Zeng F, Xia J. Proanthocyanidins inhibit pancreatic cancer AsPC-1 cell growth and migration through up-regulation of let-7a. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35:1110–5.PubMed
36.
go back to reference Kalfert D, Pesta M, Kulda V, Topolcan O, Ryska A, Celakovsky P, et al. MicroRNA profile in site-specific head and neck squamous cell cancer. Anticancer Res. 2015;35:2455–63.PubMed Kalfert D, Pesta M, Kulda V, Topolcan O, Ryska A, Celakovsky P, et al. MicroRNA profile in site-specific head and neck squamous cell cancer. Anticancer Res. 2015;35:2455–63.PubMed
37.
go back to reference Wu A, Wu K, Li J, Mo Y, Lin Y, Wang Y, et al. Let-7a inhibits migration, invasion and epithelial-mesenchymal transition by targeting HMGA2 in nasopharyngeal carcinoma. J Transl Med. 2015;13:105.PubMedPubMedCentral Wu A, Wu K, Li J, Mo Y, Lin Y, Wang Y, et al. Let-7a inhibits migration, invasion and epithelial-mesenchymal transition by targeting HMGA2 in nasopharyngeal carcinoma. J Transl Med. 2015;13:105.PubMedPubMedCentral
38.
go back to reference Yang MY, Chen MT, Huang PI, Wang CY, Chang YC, Yang YP, et al. Nuclear localization signal-enhanced polyurethane-short branch polyethylenimine-mediated delivery of Let-7a inhibited cancer stem-like properties by targeting the 3′-UTR of HMGA2 in anaplastic Astrocytoma. Cell Transplant. 2015;24:1431–50.PubMed Yang MY, Chen MT, Huang PI, Wang CY, Chang YC, Yang YP, et al. Nuclear localization signal-enhanced polyurethane-short branch polyethylenimine-mediated delivery of Let-7a inhibited cancer stem-like properties by targeting the 3′-UTR of HMGA2 in anaplastic Astrocytoma. Cell Transplant. 2015;24:1431–50.PubMed
39.
go back to reference Lee ST, Chu K, Oh HJ, Im WS, Lim JY, Kim SK, et al. Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol. 2011;102:19–24.PubMed Lee ST, Chu K, Oh HJ, Im WS, Lim JY, Kim SK, et al. Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol. 2011;102:19–24.PubMed
40.
go back to reference Liu Q, Liu T, Zheng S, Gao X, Lu M, Sheyhidin I, et al. HMGA2 is down-regulated by microRNA let-7 and associated with epithelial-mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs. Histopathology. 2014;65:408–17.PubMed Liu Q, Liu T, Zheng S, Gao X, Lu M, Sheyhidin I, et al. HMGA2 is down-regulated by microRNA let-7 and associated with epithelial-mesenchymal transition in oesophageal squamous cell carcinomas of Kazakhs. Histopathology. 2014;65:408–17.PubMed
41.
go back to reference Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol. 2009;22:431–41.PubMed Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol. 2009;22:431–41.PubMed
42.
go back to reference Ali A, Zhang P, Liangfang Y, Wenshe S, Wang H, Lin X, et al. KLF17 empowers TGF-beta/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression. Cell Death Dis. 2015;6:e1681.PubMedPubMedCentral Ali A, Zhang P, Liangfang Y, Wenshe S, Wang H, Lin X, et al. KLF17 empowers TGF-beta/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression. Cell Death Dis. 2015;6:e1681.PubMedPubMedCentral
43.
go back to reference Yu JR, Tai Y, Jin Y, Hammell MC, Wilkinson JE, Roe JS, et al. TGF-beta/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis. Genes Dev. 2015;29:250–61.PubMedPubMedCentral Yu JR, Tai Y, Jin Y, Hammell MC, Wilkinson JE, Roe JS, et al. TGF-beta/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis. Genes Dev. 2015;29:250–61.PubMedPubMedCentral
44.
go back to reference Qiao P, Li G, Bi W, Yang L, Yao L, Wu D. microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. BMC Cancer. 2015;15:469.PubMedPubMedCentral Qiao P, Li G, Bi W, Yang L, Yao L, Wu D. microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway. BMC Cancer. 2015;15:469.PubMedPubMedCentral
45.
go back to reference Guo W, Zhang M, Guo Y, Shen S, Guo X, Dong Z. FBXO32, a new TGF-beta/Smad signaling pathway target gene, is epigenetically inactivated in gastric cardia adenocarcinoma. Neoplasma. 2015;62:646–57.PubMed Guo W, Zhang M, Guo Y, Shen S, Guo X, Dong Z. FBXO32, a new TGF-beta/Smad signaling pathway target gene, is epigenetically inactivated in gastric cardia adenocarcinoma. Neoplasma. 2015;62:646–57.PubMed
46.
go back to reference Zhao HW, Li YW, Feng R, Yu JB, Li J, Zhang Y, et al. TGF-beta/Smad2/3 signal pathway involves in U251 cell proliferation and apoptosis. Gene. 2015;562:76–82.PubMed Zhao HW, Li YW, Feng R, Yu JB, Li J, Zhang Y, et al. TGF-beta/Smad2/3 signal pathway involves in U251 cell proliferation and apoptosis. Gene. 2015;562:76–82.PubMed
47.
go back to reference Ren G, Sheng L, Liu H, Sun Y, An Y, Li Y. The crucial role of SRPK1 in TGF-beta-induced proliferation and apoptosis in the esophageal squamous cell carcinomas. Med Oncol. 2015;32:209.PubMed Ren G, Sheng L, Liu H, Sun Y, An Y, Li Y. The crucial role of SRPK1 in TGF-beta-induced proliferation and apoptosis in the esophageal squamous cell carcinomas. Med Oncol. 2015;32:209.PubMed
48.
go back to reference Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol. 2011;223:205–18.PubMed Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol. 2011;223:205–18.PubMed
49.
go back to reference Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, ten Dijke P. The TGF-beta/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat. 2011;128:657–66.PubMed Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, ten Dijke P. The TGF-beta/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat. 2011;128:657–66.PubMed
Metadata
Title
RETRACTED ARTICLE: Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2
Authors
Yang Li
Xianfeng Zhang
Dawei Chen
Chengyuan Ma
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4674-6

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine